Point/Counterpoint #2-Reference-Cited by-同舟云学术

Point/Counterpoint #2

Published:2024-07 Issue:4 Volume:30 Page:256-263
ISSN:1540-336X
Container-title:The Cancer Journal
language:en
Short-container-title:Cancer J

Author:

Rajeev-Kumar Greeshma¹,Katipally Rohan R.¹,Li Shen²,Shogan Benjamin D.³,Olortegui Kinga S.³,Chin Janet⁴,Polite Blase N.⁴,Liauw Stanley L.¹

Affiliation:

1. Department of Radiation and Cellular Oncology

2. Surgical Oncology

3. Colon and Rectal Surgery, Department of Surgery

4. Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL.

Abstract

Abstract Locally advanced rectal cancer has historically been treated with multimodal therapy consisting of radiation therapy, chemotherapy, and total mesorectal excision. However, recent prospective trials and registry studies have demonstrated similar disease outcomes with nonoperative management for patients who experience an excellent clinical response to radiation and chemotherapy. This article reviews data regarding nonoperative management for rectal cancer, and highlights current challenges and limitations in a point-counterpoint format, in the context of two clinical cases.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference84 articles.

1. Organ preservation in rectal cancer: an overview of the Dutch perspective and recent developments;Clin Oncol,2023

2. Significant improvement in postoperative and 1-year mortality after colorectal cancer surgery in recent years;Eur J Surg Oncol,2019

3. Meta-analysis of oncological outcomes after local excision of pT1–2 rectal cancer requiring adjuvant (chemo)radiotherapy or completion surgery;Br J Surg,2016

4. Anastomotic leakage after anterior resection for rectal cancer: risk factors;Colorectal Dis,2010

5. Population-based cohort study of the impact on postoperative mortality of anastomotic leakage after anterior resection for rectal cancer;BJS Open,2019